5 results about "Salmeterol" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to combined application of salmeterol and an FASN inhibitor in preparation of a medicine for treating lung cancer. Compared with a single-drug FASN inhibitor, the use of the salmeterol combined FASN inhibitor has multiple advantages. It is found for the first time that the salmeterol combined with the FASN inhibitor can improve the treatment effect of the FASN inhibitor on lung cancer, the drug resistance of lung cancer cells is reduced, and the lifetime of a patient is prolonged. In addition, the salmeterol is combined with the FASN inhibitor, so that the side effect of the FASN inhibitor can be reduced, the salmeterol targeted lung cancer cells are more specific, non-specific injury can be avoided, and the living quality of patients is improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of salmeterol in preparation of a medicine for treating non-small cell lung cancer. It is found for the first time that the compound salmeterol is an effective inhibitor of asparagine synthetase (ASNS), and the compound salmeterol inhibits the biological activity and / or protein expression level of the ASNS by directly targeting the ASNS, so that a synthetic pathway of endogenous asparagine of cells is blocked. On the basis, salmeterol directly targets ASNS, inhibits the activity and / or expression level of ASNS, blocks synthesis of endogenous asparagine, and further inhibits tumor cell proliferation and induces tumor cell apoptosis. The new application of salmeterol as the ASNS inhibitor is innovatively found, a new mechanism, a new medicine and a new scheme are provided for treatment of the non-small cell lung cancer, and the salmeterol has important clinical application prospects and scientific value.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The invention provides a liquid pharmaceutical composition comprising: a) at least one long-acting muscarinic receptor antagonist (LAMA) selected from the group consisting of glycopyrronium bromide, ipratropium bromide, umiclidium bromide, and revefenacin; b) at least one long-acting adrenoceptor agonist (LABA) selected from the group consisting of formoterol fumarate, salmeterol xinofoate; alformoterol tartarate, and vilanterol trifenate; and c) at least one inhaled corticosteroid (ICS) selected from the group consisting of beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, and fluticasone propionate; and wherein the composition is in the form of a solution for aerosolization, as well as methods and devices for use of the composition.